Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 828

Showing 26-50 of 828 citing articles:

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
Haoran Ji, Chuang Hu, Xuhui Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Hypoxia signaling in cancer: Implications for therapeutic interventions
Yan Zhuang, Kua Liu, Qinyu He, et al.
MedComm (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 56
The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 56
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Cell membrane-coated nanomaterials for cancer therapy
Shiying Zeng, Qinglai Tang, Minna Xiao, et al.
Materials Today Bio (2023) Vol. 20, pp. 100633-100633
Open Access | Times Cited: 51
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 755-768
Open Access | Times Cited: 47
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 46
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 29
Oxygen‐driven cuproptosis synergizes with radiotherapy to potentiate tumor immunotherapy
Pei Pei, Yuhong Wang, Wenhao Shen, et al.
Aggregate (2024) Vol. 5, Iss. 3
Open Access | Times Cited: 27
Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3
Qun Wang, Jinxin Wang, Dianping Yu, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101357-101357
Open Access | Times Cited: 25
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
Xi Chen, Zhijie Xu, Tongfei Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
David Danielpour
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 533-533
Open Access | Times Cited: 18
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Xueqing Kong, Jinyi Zhang, Shuwei Chen, et al.
Cancer Biology and Medicine (2024), pp. 1-11
Open Access | Times Cited: 18
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
Yue Yin, Weibo Feng, Jie Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Heterogeneity‐induced NGF‐NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti‐tumor immunotherapy with PD‐1 mAb in hepatocellular carcinoma
Xin Wang, Tongwang Yang, Shangheng Shi, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 17
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Manshi Yang, Mengying Cui, Yang Sun, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Prospects and challenges of CAR-T cell therapy combined with ICIs
Yufan Lv, Xinyu Luo, Zhuoyi Xie, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 16
Mitochondria‐Targeted Nanoadjuvants Induced Multi‐Functional Immune‐Microenvironment Remodeling to Sensitize Tumor Radio‐Immunotherapy
Zaigang Zhou, Cheng Li, Chao Li, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 16
Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors
Shiyun Xian, Xiaona Chen, Sihang Ren, et al.
Cancer Research (2024) Vol. 84, Iss. 18, pp. 3044-3057
Closed Access | Times Cited: 16
Recent strategies for evoking immunogenic Pyroptosis in antitumor immunotherapy
Zhangxin He, Dexiang Feng, Chaoji Zhang, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 375-394
Open Access | Times Cited: 15
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Michael R. Shurin, Viktor Umansky
Journal of Clinical Investigation (2022) Vol. 132, Iss. 9
Open Access | Times Cited: 64
Oral Nanomotor‐Enabled Mucus Traverse and Tumor Penetration for Targeted Chemo‐Sono‐Immunotherapy against Colon Cancer
Yingui Cao, Shengsheng Liu, Ya Ma, et al.
Small (2022) Vol. 18, Iss. 42
Closed Access | Times Cited: 61
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Xingcheng Yang, Ling Ma, Xiaoying Zhang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 56

Scroll to top